Page last updated: 2024-09-03

arg-3-hyp-7-phe-bradykinin and sch 23390

arg-3-hyp-7-phe-bradykinin has been researched along with sch 23390 in 1 studies

Compound Research Comparison

Studies
(arg-3-hyp-7-phe-bradykinin)
Trials
(arg-3-hyp-7-phe-bradykinin)
Recent Studies (post-2010)
(arg-3-hyp-7-phe-bradykinin)
Studies
(sch 23390)
Trials
(sch 23390)
Recent Studies (post-2010) (sch 23390)
52238030585

Protein Interaction Comparison

ProteinTaxonomyarg-3-hyp-7-phe-bradykinin (IC50)sch 23390 (IC50)
D(2) dopamine receptorHomo sapiens (human)1.0405
DRattus norvegicus (Norway rat)0.001
D(1A) dopamine receptorHomo sapiens (human)0.0461
D(1B) dopamine receptorHomo sapiens (human)0.0011
D(2) dopamine receptorRattus norvegicus (Norway rat)0.0006
Sigma non-opioid intracellular receptor 1Homo sapiens (human)0.3891

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Axe, FU; Bembenek, SD; Butler, CR; Coles, F; Dunford, PJ; Edwards, JP; Fourie, AM; Grice, CA; Karlsson, L; Lundeen, K; Riley, JP; Savall, BM; Tays, KL; Wei, J; Williams, KN; Xue, X1

Other Studies

1 other study(ies) available for arg-3-hyp-7-phe-bradykinin and sch 23390

ArticleYear
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.
    Journal of medicinal chemistry, 2008, Jul-24, Volume: 51, Issue:14

    Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Catalysis; Dogs; Drug Evaluation, Preclinical; Enzyme Inhibitors; Epoxide Hydrolases; Humans; Magnetic Resonance Spectroscopy; Mice; Structure-Activity Relationship

2008